UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________

Form 8-K
_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): April 219, 2018

Argos Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)

Delaware	001-35443	56-2110007
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

4233 Technology Drive, Durham, North Carolina 27704

(Address of Principal Executive Offices) (Zip Code)

(919) 287-6300
(Registrant's telephone number, including area code)

None
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
	[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company [ X ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ X ]

Item 28.0201. ~~Results~~Other ~~of Operations and Financial Condition~~Events.

On April 219, 2018, Argos Therapeutics, Inc. (the “"Company”") ~~announced~~issued ~~financial~~a press release reporting interim results from its Phase 3 ADAPT clinical trial evaluating Rocapuldencel-T for the ~~three~~treatment ~~months~~of metastatic renal cell carcinoma, and ~~year~~the ~~ended~~Company’s ~~December~~decision 31to terminate the ADAPT trial, ~~2017.~~review of strategic alternatives and expectation that its common stock will be delisted from The ~~full~~Nasdaq ~~text~~Capital ofMarket and transferred to the ~~press~~OTCQB® ~~release~~Venture ~~issued~~Market. inA ~~connection~~copy ~~with~~of the ~~announcement~~Company’s press release is ~~furnished~~attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

~~The~~99.1 ~~following~~Press ~~exhibit~~Release, ~~relating~~dated toApril ~~Item~~19, ~~2.02~~2018, ~~shall~~entitled be"Argos ~~deemed~~Therapeutics toReports beResults ~~furnished,~~of Interim Analysis of the ADAPT Trial and ~~not~~Announces ~~filed:~~Review of Strategic Alternatives"

99.1 Press release dated April 2, 2018 entitled “Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Argos Therapeutics, Inc.
Date: April 2, 2018	By:	/s/ Richard D. Katz, M.D.
Date: April 19, 2018	By:	/s/ Richard D. Katz, M.D.
		Richard D. Katz, M.D
		Vice President and Chief Financial Officer

Filing Compare · ARGOS THERAPEUTICS INC